Announcements
- Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
- Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
- Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
- Medigene to Present at Upcoming Conferences
- Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
- Medigene AG reports Financial Results and Business Update for Q1 2024
- Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
- Medigene to Present at Upcoming Scientific Conferences
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 8.76 |
Average volume | -- |
---|---|
Shares outstanding | 29.48m |
Free float | 28.61m |
P/E (TTM) | -- |
Market cap | 35.37m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jun 17 2019 12:10 BST.
More ▼